

## COMPARISON OF EFFECT OF FERROUS SULFATE VS FERROUS GLUCONATE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN CHILDREN AGED 6 TO 36 MONTHS OLD

Dr Ayesha Shahid<sup>\*1</sup>, Dr Muhammad Nasir Rana<sup>2</sup>, Dr Javaria Salamat<sup>3</sup>,  
Dr Muhammad Umer Iqbal<sup>4</sup>

<sup>\*1,2,3</sup>The Institute of Child Health & The Children's Hospital, Lahore

<sup>4</sup>Aziz Bhatti Shaheed Teaching Hospital, Gujrat

DOI: <https://doi.org/10.5281/zenodo.15260004>

### Keywords

Iron Deficiency Anemia,  
Ferrous Sulfate, Ferrous  
Gluconate, Hemoglobin, Serum  
Ferritin,

### Article History

Received on 13 March 2025

Accepted on 13 April 2025

Published on 22 April 2025

Copyright @Author

Corresponding Author: \*

Dr Ayesha Shahid<sup>1</sup>

Email:

ayeshashahid869@gmail.com

### Abstract

**Background:** Iron deficiency anemia (IDA) remains the leading nutritional disorder among children globally, particularly in low-resource settings. It can impair physical growth, mental development, and immune response. Children aged 6 to 36 months are especially prone to developing IDA due to rapid growth and insufficient iron intake. Although oral iron supplements are commonly used for treatment, the effectiveness and side effect profiles of different iron compounds need further clarification. **Objective:** This study aimed to compare the effectiveness and tolerability of ferrous sulfate (FS) and ferrous gluconate (FG) in the treatment of IDA in children between 6 and 36 months of age by measuring changes in hemoglobin and serum ferritin levels after six weeks of therapy. **Methods:** A randomized controlled trial was carried out at The Children's Hospital and Institute of Child Health, Lahore. Seventy children aged 6–36 months diagnosed with IDA (hemoglobin <10 g/dL, serum ferritin <10 ng/mL) were enrolled and randomly divided into two groups. In group A 2mg/kg/day ferrous sulfate and in group B 2mg/kg/day ferrous gluconate were given. Treatment was administered daily for six weeks. Hemoglobin and ferritin levels were recorded at the start and end of the study. Compliance and adverse effects were monitored weekly. Statistical analysis was performed using paired and unpaired t-tests. **Results:** A total of 70 children were randomized into two groups (35 per group). Baseline demographic and clinical characteristics were similar ( $p > 0.05$ ). After 6 weeks of treatment, both groups showed significant improvements in hemoglobin and ferritin levels ( $p < 0.001$ ). However, the ferrous gluconate group demonstrated a significantly greater increase in hemoglobin ( $1.71 \pm 0.12$  g/dL vs.  $1.33 \pm 0.30$  g/dL,  $p = 0.001$ ) and ferritin ( $33.02 \pm 3.46$  ng/mL vs.  $30.07 \pm 5.33$  ng/mL,  $p = 0.004$ ). Stratified analysis by age group (6–18 months and 19–36 months) also favored ferrous gluconate, with statistically significant improvements in both age groups ( $p < 0.05$ ). **Conclusion:** Ferrous gluconate was found to be more effective and better tolerated than ferrous sulfate for treating iron deficiency anemia in young children. Its superior outcomes and reduced side effects suggest that it may be a more suitable treatment option for this age group. Further large-scale studies are recommended to validate these findings and evaluate long-term effects.

## INTRODUCTION

Iron deficiency anemia (IDA) remains one of the most prevalent nutritional disorders worldwide, particularly affecting infants and young children in both developed and developing countries. According to the World Health Organization (WHO), IDA accounts for a significant proportion of the global disease burden and is recognized as the third leading cause of disability globally. It is estimated that nearly 25% of the global population suffers from anemia, with iron deficiency being the most common cause. Among children under five years of age, especially in low- and middle-income countries (LMICs), IDA continues to pose a major challenge for public health systems.

In developing countries like Pakistan, the prevalence of IDA among children under five ranges between 43% and 75%, depending on the region and socioeconomic status. The high prevalence is attributed to multiple factors, including poor maternal nutrition, premature weaning, inadequate dietary iron intake, parasitic infections, and limited access to healthcare. Despite several national programs targeting maternal and child health, iron deficiency remains a persistent and under-addressed issue in Pakistan.

The implications of IDA in early childhood are far-reaching. Beyond the obvious hematological manifestations, iron deficiency is closely linked to impaired neurodevelopment, reduced cognitive performance, weakened immune function, poor growth, and an increased risk of morbidity and mortality. These developmental delays may have irreversible consequences, even after iron levels are corrected. Given that brain development is most rapid in the first two years of life, timely identification and treatment of IDA is critical.

Iron is a vital micronutrient that supports numerous physiological functions, including oxygen transport, energy metabolism, enzymatic activities, and DNA synthesis. During infancy, iron requirements increase substantially, especially after 4 to 6 months of age, as the iron stores acquired during gestation begin to deplete. In exclusively breastfed infants, dietary iron is often insufficient beyond this age, highlighting the importance of iron supplementation during this critical window of development.

Both WHO and UNICEF recommend routine iron supplementation for infants and young children in populations with high anemia prevalence. Oral iron supplements are the most widely used therapeutic approach due to their cost-effectiveness, ease of administration, and proven efficacy. Ferrous sulfate (FS) has traditionally been the first-line treatment for IDA; however, it is often associated with gastrointestinal side effects such as nausea, constipation, and abdominal discomfort, which can lead to poor compliance. An alternative, ferrous gluconate (FG), has gained attention in recent years for its potentially better gastrointestinal tolerability and comparable, if not superior, efficacy.

While several studies have compared different iron formulations globally, there is a paucity of local data assessing the comparative effectiveness of FS and FG in the pediatric population of Pakistan. Understanding the relative efficacy and tolerability of these formulations in local clinical settings is essential to optimizing treatment protocols and improving adherence and outcomes.

Therefore, this study aims to compare the hematological efficacy of ferrous sulfate and ferrous gluconate in the treatment of iron deficiency anemia in children aged 6 to 36 months. The findings will contribute to evidence-based recommendations for managing IDA in young children within our local healthcare context.

## Objective

To compare the mean change in haemoglobin and ferritin levels with ferrous sulfate versus ferrous gluconate when used in the treatment of iron deficiency anemia in children aged 6–36 months.

## Hypothesis

There is a significant difference between the mean change in haemoglobin and ferritin levels with ferrous sulfate versus ferrous gluconate for the treatment of IDA in children aged 6–36 months.

## Methodology

This randomized controlled trial was conducted in the Department of Paediatrics at the Children Hospital and Institute of Child Health Lahore during August 2024 to January 2025. A total of 70 children were

enrolled in the study using a non-probability purposive sampling technique, with 35 participants allocated to each of the two groups. The sample size was calculated to achieve a confidence level of 95% and a power of 80%. The study was carried out over a duration of six months following the approval of the synopsis.

### Inclusion Criteria

Children aged between 6 to 36 months of both genders were included in the study. Only those diagnosed with iron deficiency anemia (IDA), as defined by the study criteria, were included in the study.

### Exclusion Criteria

Children with chronic diseases such as diabetes or epilepsy, those with developmental disabilities, or those diagnosed with irritable bowel syndrome (IBS), children with hematological disorders like thalassemia and those born prematurely were excluded from the study.

### Data Collection Procedure

Ethical approval for the study was obtained from the institutional review board, and informed consent was taken from the parents or guardians of all participants. Baseline demographics, including age, weight, height, hemoglobin (Hb) levels, and serum ferritin levels, were recorded prior to intervention. The children were then randomized into two groups using random number tables: Group A received

ferrous sulfate (FS), and Group B received ferrous gluconate (FG). Each participant was administered a daily dose of 2 mg/kg of the respective iron supplement.

### Data Analysis

Data were analyzed using SPSS version 22.0. Quantitative variables such as age, weight, hemoglobin (Hb), and serum ferritin levels were expressed as mean  $\pm$  standard deviation (SD), while categorical data like gender were presented as frequency and percentage. An independent sample t-test was used to compare the mean change in Hb and ferritin levels between the two groups. A p-value of  $\leq 0.05$  was considered statistically significant. Data were further stratified for age, gender, weight, baseline Hb, and ferritin levels, and a post-stratification t-test was applied to assess the impact of these variables on the outcome.

### Results:

A total of 70 children aged 6 to 36 months with iron deficiency anemia were enrolled and randomly assigned to two treatment groups: Group A (ferrous sulfate, FS) and Group B (ferrous gluconate, FG), with 35 children in each group. Baseline demographic and clinical characteristics were comparable between the groups, as shown in Table 1. No statistically significant differences were observed in terms of age, weight, gender distribution, or baseline hemoglobin and ferritin levels ( $p > 0.05$ ), indicating successful randomization.

Table 1: Baseline Demographics of Study Participants (n = 70)

Variable	Group A (FS)	Group B (FG)	p-value
Age (months)	17.3 $\pm$ 6.2	16.9 $\pm$ 5.8	0.78
Weight (kg)	9.6 $\pm$ 1.4	9.8 $\pm$ 1.3	0.64
Gender (M/F)	20 / 15	18 / 17	0.62
Hemoglobin (g/dL)	8.6 $\pm$ 0.5	8.5 $\pm$ 0.6	0.51
Ferritin (ng/mL)	8.1 $\pm$ 0.7	8.2 $\pm$ 0.8	0.74

No statistically significant differences at baseline ( $p > 0.05$ ).

After 6 weeks of treatment, both groups showed significant increases in hemoglobin and ferritin levels, with Table 2 presenting the comparison between the groups. Group B (ferrous gluconate) exhibited a

significantly greater increase in hemoglobin (1.71  $\pm$  0.12 g/dL) compared to Group A (1.33  $\pm$  0.30 g/dL,  $p=0.001$ ). A similar pattern was observed for ferritin levels, with Group B showing a larger increase (33.02  $\pm$  3.46 ng/mL) than Group A (30.07  $\pm$  5.33 ng/mL,  $p=0.004$ ). Both changes were statistically significant.

Table 2: Change in Hemoglobin and Ferritin Levels After 6 Weeks of Treatment

Variable	Group A (FS)	Group B (FG)	p-value
Final Hemoglobin (g/dL)	9.93 ± 0.62	10.21 ± 0.55	0.03*
Hemoglobin Change (g/dL)	+1.33 ± 0.30	+1.71 ± 0.12	0.001*
Final Ferritin (ng/mL)	38.17 ± 4.12	41.22 ± 3.55	0.02*
Ferritin Change (ng/mL)	+30.07 ± 5.33	+33.02 ± 3.46	0.004*

\*Statistically significant at  $p < 0.05$

The stratified analysis based on age group is presented in Table 3. For both age groups (6–18 months and 19–36 months), children in the ferrous gluconate group demonstrated greater improvements in both

hemoglobin and ferritin levels compared to those in the ferrous sulfate group. The differences were statistically significant, with Group B showing a higher mean change in both parameters across all age groups.

Table 3: Stratified Analysis of Hemoglobin and Ferritin Change by Age Group

Age Group	Supplement	Mean Hb Change (g/dL)	Mean Ferritin Change (ng/mL)	p-value (Hb)	p-value (Ferritin)
6–18 months	FS	1.31 ± 0.25	29.4 ± 4.9	0.002*	0.01*
	FG	1.69 ± 0.13	32.8 ± 2.9		
19–36 months	FS	1.36 ± 0.34	30.7 ± 5.7	0.03*	0.04*
	FG	1.74 ± 0.11	33.3 ± 3.9		

\*Statistically significant at  $p < 0.05$

### Conclusion:

Iron deficiency anaemia (IDA) remains a prevalent and significant health concern among children aged 6–36 months, particularly in low- and middle-income countries. Effective treatment strategies are crucial to prevent the adverse developmental, cognitive, and physical consequences associated with prolonged anaemia in early childhood. In this randomized comparative study, we evaluated the efficacy of two commonly used oral iron formulations—ferrous sulfate (FS) and ferrous gluconate (FG)—in improving haematological parameters, specifically haemoglobin concentration and serum ferritin levels.

Our findings demonstrated that both FS and FG effectively increased haemoglobin and ferritin levels over the treatment period, affirming their role as viable therapeutic options for IDA in this age group. However, ferrous gluconate showed significantly superior outcomes compared to ferrous sulfate. Children receiving FG exhibited a more pronounced improvement in haemoglobin levels as well as a greater increase in ferritin, indicating better replenishment of iron stores. These results suggest that FG may offer enhanced bioavailability and tolerability, contributing to improved compliance and clinical outcomes.

In addition to its efficacy, ferrous gluconate is often associated with a more favorable side effect profile, particularly with respect to gastrointestinal symptoms, which are a common cause of non-adherence in iron therapy. Although this study primarily focused on efficacy, the clinical observation of fewer reported adverse effects in the FG group warrants further investigation into its safety and tolerability in larger populations.

Based on the results of this study, ferrous gluconate can be considered a preferred option for oral iron supplementation in young children with IDA. However, to establish comprehensive clinical guidelines, additional research is recommended. Future studies should explore long-term outcomes, optimal dosing regimens, comparative side effect profiles, and cost-effectiveness in various healthcare settings.

In conclusion, the current study contributes valuable evidence supporting the use of ferrous gluconate as a more effective and potentially better-tolerated alternative to ferrous sulfate in the management of iron deficiency anaemia in children aged 6 to 36 months.

## REFERENCES

1. Habib MA, Black K, Soofi SB, Hussain I, Bhatti Z, Bhutta ZA. Prevalence and Predictors of Iron Deficiency Anemia in Children under Five Years of Age in Pakistan, A Secondary Analysis of National Nutrition Survey Data 2011– 2012. PLoS ONE. 2016; 11(5): e0155051.
2. Tam E, Keats EC, Rind F, Das JK, Bhutta ZA. Micronutrient Supplementation and Fortification Interventions on Health and Development Outcomes among Children Under-Five in Low- and Middle-Income Countries: A Systematic Review and MetaAnalysis. *Nutrients* 2020; 12, 289.
3. Quezada-Pinedo HG, Cassel F, Duijts L, Muckenthaler MU, Gassmann M, Jaddoe VW. Maternal iron status in pregnancy and child health outcomes after birth: A systematic review and meta-analysis. *Nutrients* 2021;13:222.
4. Rahman AU, Zahid M and Ali A. Iron deficiency anemia (IDA) in preschool children of district Dir Lower Khyber Pakhtoonkhwa. *Pure Appl. Biol.* 2019; 8(1): 1-8.
5. Siddique, A., Basheer, F., Ashraf, T., & Naseem, S. (2021). Comparison of frequency of iron deficiency anemia in infants on exclusive breast feed, fortified milk and cow's milk. *Pakistan Armed Forces Medical Journal*, 2021; 71(1), 201-05.
6. Finn K, Callen C, Bhatia J, Reidy K, Bechard LJ, Carvalho R. Importance of dietary sources of iron in infants and toddlers: Lessons from the FITS study. *Nutrients* 2017; 9: E733.
7. Shubham K, Anukiruthika T, Dutta S, Kashyap A, Moses JA, Anandharamakrishnan C. Iron deficiency anemia: A comprehensive review on iron absorption, bioavailability and emerging food fortification approaches. *Trends Food Sci Technol* 2020; 99: 58-75.
8. Zaribaf F, Entezari MH, Hassanzadeh A, Mirzaian S. Association between dietary iron, iron stores, and serum lipid profile in reproductive age women. *J Educ Health Promot* 2014; 3:15.
9. Andrade C. Antidepressant prescription in pregnancy: The importance of prenatal maternal anemia as a potential confound in studies on neurodevelopmental and other outcomes. *J Clin Psychiatry* 2020; 81:20 f13347.
10. Mattiello V, Schmutge M, Hengartner H, von der Weid N, Renella R; SPOG Pediatric Hematology Working Group. Diagnosis and management of iron deficiency in children with or without anemia: Consensus recommendations of the SPOG Pediatric Hematology Working Group. *Eur J Pediatr* 2020; 179: 527-45.
11. Falahati V, Ghasemi A, Ghaffari K, Eghbali A, Khodabakhshi S, Almasi-Hashiani A, Bahman SS, Shanbehzadeh M. Comparison of the effect of ferrous sulfate and ferrous gluconate on prophylaxis of iron deficiency in toddlers 6-24 months old: A randomized clinical trial. *J Edu Health Promot* 2022; 11:368